Learn more about MetaVia's positive top-line data from its Phase 2a clinical trial of DA-1241, a GPR119 agonist, in patients with presumed MASH, at the 9th Annual MASH-TAG 2025 Conference. Read more about participation at MASH-TAG: https://lnkd.in/eyxD_WMV Read the DA-1241 Phase 2a data press release: https://bit.ly/DA-1241
MetaVia
生物技术研究
Cambridge，Massachusetts 1,137 位关注者
Novel treatments for chronic liver and related metabolic disease
关于我们
MetaVia (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for once-a-week injection. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. Our strategic partner and the largest investor, Dong-A ST Co. Ltd., is part of the Dong-A Socio Group of companies established in 1932 and based in South Korea. MetaVia has the full support of Dong-A ST’s Research Center, providing the company with access to R&D, scientific and CMC expertise.
- 网站
-
https://www.metaviatx.com/
MetaVia的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- Cambridge，Massachusetts
- 类型
- 上市公司
- 创立
- 2017
- 领域
- Diabetes、MASH、Obesity和Cardiometabolic Diseases
地点
-
主要
获取路线
545 Concord Ave
US，Massachusetts，Cambridge，02138
MetaVia员工
动态
-
MetaVia转发了
Analyst Sees Major Growth for Biopharma With Weight-Loss Drug: https://ow.ly/KFF850UypSw Recent successes of weight-loss drugs like Ozempic and Wegovy have led H.C. Wainwright & Co. Analyst Ed Arce to be "intrigued" by MetaVia's new drug candidate. $MTVA
-
MetaVia has announced positive top-line 16-week results from its Phase 2a clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed MASH. In this trial, DA-1241 (100mg) demonstrated a statistically significant reduction in ALT levels at weeks 4 and 8, with a near statistically significant reduction at week 16. Read more in the press release: https://bit.ly/MTVADA1241
-
-
MetaVia (formerly NeuroBo Pharmaceuticals) presented at the Investor Summit highlighting their pipeline on next generation therapeutics targeting obesity and MASH. View the presentation here: https://lnkd.in/eSrbG-Fv
-
-
MetaVia is proud to have been featured on the Nasdaq Tower on Friday, 11/29, to coincide with the company’s rebranding. Hyung Heon Kim, President and Chief Executive Officer of MetaVia commented, "Our corporate name change to MetaVia, ahead of important clinical milestones, represents the final step in our transition to developing innovative therapies for the management of cardiometabolic diseases, targeting the obesity and metabolic dysfunction-associated steatohepatitis (MASH) markets." Read more about the corporate name change in the press release:?https://lnkd.in/eqD63Rcf
-
-
MetaVia转发了
$MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
scr.zacks.com
-
Ahead of a number of important clinical milestones, we have announced a corporate name change to “MetaVia Inc.” (Nasdaq: MTVA). Read more about our strategic realignment in the press release:?https://lnkd.in/eqD63Rcf
-